AstraZeneca (NASDAQ: AZN) announced its first interim efficacy results for its COVID-19 vaccine last week. But the National Institutes of Health (NIH) quickly released a statement that seemed to slap the drugmaker's wrist for not including more up-to-date results. In this Motley Fool Live video recorded on March 24, 2021 , Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AstraZeneca's COVID-19 vaccine can still be a winner in the U.S. market after its public relations fiasco. (Note: AstraZeneca subsequently announced updated efficacy results on March 25 after this video was recorded.)
For further details see:
Can AstraZeneca Win in the U.S. COVID Vaccine Market After Its Efficacy Results Fiasco?